undamentalytics Newsletter
Sign in

Fulgent Genetics, Inc. revenue

Fulgent Genetics, Inc.'s revenue was $323m in fiscal 2025, up 13.8% on the year before. Since fiscal 2014 ($1.3m) it has grown at a compound 65.3% a year. Over the last twelve months it was $324m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue11018192133422993619289283323324
Growth on the year before—+649.3%+90.9%+2.5%+14.0%+52.3%+>999%+135.4%−37.6%−53.3%−2.0%+13.8%—
Gross profit0512101118332777367104107131115
Gross margin26.8%47.1%63.2%54.3%49.9%56.6%78.7%78.3%59.3%36.1%37.8%40.6%35.6%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Laboratory Services $322M 99.9% ▲ 13.7%
Therapeutic Development $447,000 0.1% —
Geography
Region Revenue Share YoY
United States $297M 91.9% ▲ 14.4%
Outside the US $26.1M 8.1% ▲ 7.3%
Other Countries $13.2M 50.6% ▲ 12.9%
China $12.9M 49.4% ▲ 2.1%

From Fulgent Genetics, Inc.'s 10-K filed February 27, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Life Sciences Tools & Services: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Fulgent Genetics, Inc. $324m 6.8% 1.8%
Castle Biosciences Inc $357m 3.2% 28.7%
Schrodinger, Inc. $259m 8.9% 10.2%
Mesa Laboratories Inc $250m 3.0% 4.4%
Twist Bioscience Corp $432m 19.2% 22.4%
Maravai Lifesciences Holdings, Inc. $209m -5.0% -27.3%

Compare with peers

Head to head: CSTL vs FLGTFLGT vs SDGRFLGT vs MLABFLGT vs TWST

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Fulgent Genetics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Fulgent Genetics, Inc.